Last Updated on
Most children with this disease do not survive past early childhood due to respiratory failure. These children now have a exciting treatment option to minimize the progression of SMA and improve survival. Overall, Onasemnogene Abeparvovec-xioi (Zolgensma) is indicated for the treatment of children less than two years of age with SMA. The product is an adeno-associated virus vector-based gene therapy that targets the cause of SMA. The vector delivers a fully functional copy of human SMN gene into the target motor neuron cells. A one-time intravenous administration of Onasemnogene Abeparvovec-xioi (Zolgensma) results in expression of the SMN protein in a child’s motor neurons, which improves muscle movement and function, and survival. Dosing is determined based on the weight of the patient.
The safety and effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) is based on an ongoing clinical trial and a completed clinical trial involving a total of 36 pediatric patients with infantile-onset SMA between the ages of approximately 2 weeks and 8 months at study entry. The primary evidence of effectiveness is based on results from the 21 patients treated with Onasemnogene Abeparvovec-xioi (Zolgensma) in the ongoing clinical trial. In this trial, there are 19 remaining patients, who range in age from 9.4 to 18.5 months; 13 of these 19 patients are at least 14 months of age. Compared to the natural history of patients with infantile-onset SMA, patients treated with Onasemnogene Abeparvovec-xioi (Zolgensma) also demonstrated significant improvement in their ability to reach developmental motor milestones (e.g., head control and the ability to sit without support).
The most common side effects of Onasemnogene Abeparvovec-xioi (Zolgensma) are elevated liver enzymes and vomiting. Onasemnogene Abeparvovec-xioi (Zolgensma) has a boxed warning that acute serious liver injury can occur. Patients with pre existing liver impairment may be at higher risk of experiencing serious liver injury. Clinical examination and laboratory tests to assess liver function should be completed prior to treatment with Onasemnogene Abeparvovec-xioi (Zolgensma), and patients’ liver function should be monitored for at least three months after Onasemnogene Abeparvovec-xioi (Zolgensma) administration. Moreover, certain vaccines are contraindicated for patients on a substantially immunosuppressive steroid dose. Therefore, caregivers should consult with their healthcare professional to determine if adjustments to the patient’s vaccination schedule are necessary to accommodate concomitant corticosteroid administration.
Noteworthy, the FDA granted this application Fast Track, Breakthrough Therapy, and Priority Review designations. Onasemnogene Abeparvovec-xioi (Zolgensma) also received Orphan Drug designation, which provides incentives to encourage the development of drugs for rare diseases. Furthermore, the FDA also awarded the manufacturer a rare pediatric disease priority review voucher, under a program intended to encourage the development of new drugs and biological products for the prevention and treatment of certain rare pediatric diseases. See also here a pivotal published study on gene replacement in the treatment of spinal muscular atrophy,